Name | BSJ-04-132 |
---|
Description | BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC50s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity[1]. |
---|---|
Related Catalog | |
Target |
CDK4/D1:50.6 nM (IC50) CDK6/D1:30 nM (IC50) |
In Vitro | BSJ-04-132 (0.1-5 μM; for 4 hours) only resultes in degradation of CDK4 in WT cells, not CDK6 and IKZF1/3[1]. Western Blot Analysis[1] Cell Line: Wildtype (WT) or Crbn-/- Jurkat cells Concentration: 0.1, 0.5, 1, 5 μM Incubation Time: For 4 hours Result: Only resulted in degradation of CDK4 in WT cells, not CDK6 and IKZF1/3. |
References |
Molecular Formula | C42H49N11O7 |
---|---|
Molecular Weight | 819.91 |
Hazard Codes | Xi |
---|